Recent Company News

• 09:14 AM ET Jun 10, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:14 AM ET Jun 11, 2025
  

  StreetAccount Summary - US Pre-market trading

• 04:04 PM ET Jun 30, 2025
  

  i-mab announces publication of Givastomig Monotherapy data in clinical cancer research ($2.42, 0.00)

• 10:00 AM ET Jun 30, 2025
  

  Why Early-Onset Cancers Are Alarming Researchers--and What It Means for Investors

• 06:35 AM ET Jun 26, 2025
  

  I-Mab highlights givastomig phase 1B dose escalation data in combination with Immunochemotherapy in patients with 1L gastric cancers at ESMO GI 2025 ($2.78, 0.00)